{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T20:01:52Z","timestamp":1794340912450,"version":"4.9.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:00:00Z","timestamp":1731196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Cardiovascular Imaging"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jcmg.2024.10.011","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T14:14:03Z","timestamp":1736345643000},"page":"478-499","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"title":["The Last Decade in Cardiac Amyloidosis"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-2078","authenticated-orcid":false,"given":"Marianna","family":"Fontana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5017-8657","authenticated-orcid":false,"given":"Adam","family":"Ioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Cuddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1462-1185","authenticated-orcid":false,"given":"Sharmila","family":"Dorbala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-6526","authenticated-orcid":false,"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasvi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7725-9318","authenticated-orcid":false,"given":"Olivier","family":"Clerc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6424-4413","authenticated-orcid":false,"given":"Fredrick","family":"Ruberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Gillmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcmg.2024.10.011_bib1","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jcmg.2024.10.011_bib2","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC State-of-the-Art Review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2024.10.011_bib3","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2024.10.011_bib4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/CIRCIMAGING.123.015259","article-title":"Rare forms of cardiac amyloidosis: diagnostic clues and phenotype in Apo AI and AIV amyloidosis","volume":"16","author":"Ioannou","year":"2023","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.10.011_bib5","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1002\/ejhf.2646","article-title":"Sex differences among patients with transthyretin amyloid cardiomyopathy\u2014from diagnosis to prognosis","volume":"24","author":"Patel","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jcmg.2024.10.011_bib6","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ejhf.2776","article-title":"Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy","volume":"25","author":"Porcari","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jcmg.2024.10.011_bib7","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A\u00a0new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2024.10.011_bib8","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2024.10.011_bib9","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2024.10.011_bib10","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Castano","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2024.10.011_bib11","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction","volume":"6","author":"Abouezzeddine","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jcmg.2024.10.011_bib12","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jcmg.2018.02.016","article-title":"Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles","volume":"12","author":"Knight","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.10.011_bib13","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1161\/CIRCIMAGING.113.000683","article-title":"Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy","volume":"6","author":"Liu","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.10.011_bib14","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.echo.2020.03.012","article-title":"Reduced diagnostic accuracy of apical-sparing strain abnormality for cardiac amyloidosis in patients with chronic kidney disease","volume":"33","author":"Singh","year":"2020","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jcmg.2024.10.011_bib15","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.122.014645","article-title":"Optimal echocardiographic parameters to improve the diagnostic yield of Tc-99m\u2013bone avid tracer cardiac scintigraphy for transthyretin cardiac amyloidosis","volume":"15","author":"Cuddy","year":"2022","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.10.011_bib16","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jcmg.2019.10.011","article-title":"Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis","volume":"13","author":"Boldrini","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.10.011_bib17","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/ehjci\/jeac049","article-title":"Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis","volume":"23","author":"Giblin","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.10.011_bib18","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.jcmg.2024.10.011_bib19","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/ehjci\/jeae021","article-title":"Limitations of apical sparing pattern in cardiac amyloidosis: a multicentre echocardiographic study","volume":"25","author":"Cotella","year":"2024","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.10.011_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-22877-8","article-title":"Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms","volume":"12","author":"Goto","year":"2021","journal-title":"Nat Comm"},{"key":"10.1016\/j.jcmg.2024.10.011_bib21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcmg.2021.06.022","article-title":"Clinical importance of left atrial infiltration in cardiac transthyretin amyloidosis","volume":"15","author":"Bandera","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.10.011_bib22","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jacc.2019.01.035","article-title":"High prevalence of intracardiac thrombi in cardiac amyloidosis","volume":"73","author":"Martinez-Naharro","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2024.10.011_bib23","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/eurheartj\/ehz905","article-title":"Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis","volume":"41","author":"Chacko","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2024.10.011_bib24","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/ejhf.2606","article-title":"Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis","volume":"24","author":"Chacko","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jcmg.2024.10.011_bib25","first-page":"464","article-title":"Multi-imaging characterization of cardiac phenotype in different types of amyloidosis","volume":"14","author":"Ioannou","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.10.011_bib26","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJM199008233230803","article-title":"Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component","volume":"323","author":"Hawkins","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmg.2024.10.011_bib27","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","article-title":"Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis","volume":"132","author":"Fontana","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2024.10.011_bib28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcmg.2013.10.008","article-title":"Native T1 mapping in transthyretin amyloidosis","volume":"7","author":"Fontana","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.10.011_bib29","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1148\/radiol.2015141744","article-title":"Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: a cardiac MR imaging study","volume":"277","author":"Fontana","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.jcmg.2024.10.011_bib30","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jcmg.2023.02.019","article-title":"Tracking multiorgan treatment response in systemic AL-amyloidosis with cardiac magnetic resonance derived extracellular volume mapping","volume":"16","author":"Ioannou","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.10.011_bib31","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1016\/j.jacc.2018.03.536","article-title":"Myocardial edema and prognosis in amyloidosis","volume":"71","author":"Kotecha","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2024.10.011_bib32","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/ejhf.3137","article-title":"Myocardial perfusion in cardiac amyloidosis","volume":"26","author":"Chacko","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jcmg.2024.10.011_bib33","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2024.10.011_bib34","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1016\/j.jacc.2020.04.022","article-title":"Cardiac scintigraphy with technetium-99m\u2013labeled bone-seeking tracers for suspected amyloidosis: JACC Review Topic of the Week","volume":"75","author":"Hanna","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2024.10.011_bib35","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/ehjci\/jeab095","article-title":"99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis","volume":"22","author":"Quarta","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.10.011_bib36","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2024.10.011_bib37","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1093\/eurheartj\/ehad139","article-title":"Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis","volume":"24","author":"Rauf","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2024.10.011_bib38","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2\u2014evidence base and standardized methods of imaging","volume":"26","author":"Dorbala","year":"2019","journal-title":"J\u00a0Nucl Cardiol"},{"key":"10.1016\/j.jcmg.2024.10.011_bib39","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s12350-022-02989-4","article-title":"Echocardiographic indices of left ventricular function and filling pressure are not related to blood pool activity on pyrophosphate scintigraphy","volume":"30","author":"Asif","year":"2023","journal-title":"J\u00a0Nucl Cardiol"},{"key":"10.1016\/j.jcmg.2024.10.011_bib40","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s12350-020-02353-4","article-title":"Inter-observer reproducibility and intra-observer repeatability in 99mTc-pyrophosphate scan interpretation for diagnosis of transthyretin cardiac amyloidosis","volume":"29","author":"Singh","year":"2022","journal-title":"J\u00a0Nucl Cardiol"},{"key":"10.1016\/j.jcmg.2024.10.011_bib41","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s12350-015-0261-x","article-title":"Serial scanning with technetium pyrophosphate (99mTc-PYP) in advanced ATTR cardiac amyloidosis","volume":"23","author":"Casta\u00f1o","year":"2016","journal-title":"J\u00a0Nucl Cardiol"},{"key":"10.1016\/j.jcmg.2024.10.011_bib42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.10.011_bib43","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ejhf.3138","article-title":"Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy","volume":"26","author":"Garcia-Pavia","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jcmg.2024.10.011_bib44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/13506129.2018.1520087","article-title":"Quantitation of 99mTc-DPD uptake in patients with transthyretin-related cardiac amyloidosis","volume":"25","author":"Ross","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.jcmg.2024.10.011_bib45","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2967\/jnumed.111.102053","article-title":"In\u00a0vivo visualization of amyloid deposits in the heart with 11C-PIB and PET","volume":"54","author":"Antoni","year":"2013","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.jcmg.2024.10.011_bib46","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcmg.2014.09.018","article-title":"11C-Pittsburgh B PET imaging in cardiac amyloidosis","volume":"8","author":"Lee","year":"2015","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.10.011_bib47","first-page":"1368","article-title":"How to image cardiac amyloidosis: a practical approach","volume":"13","author":"Dorbala","year":"2020","journal-title":"Cardiovasc Imaging"},{"issue":"8","key":"10.1016\/j.jcmg.2024.10.011_bib48","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.114.002954","article-title":"18F-Florbetapir binds specifically to myocardial light chain and transthyretin amyloid deposits","volume":"8","author":"Park","year":"2015","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.10.011_bib49","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1007\/s00259-014-2787-6","article-title":"Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomography","volume":"41","author":"Dorbala","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jcmg.2024.10.011_bib50","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcmg.2020.05.031","article-title":"[18F]-Florbetaben PET\/CT for differential diagnosis among cardiac immunoglobulin light chain, transthyretin amyloidosis, and mimicking conditions","volume":"14","author":"Genovesi","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.10.011_bib51","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jcmg.2020.02.025","article-title":"Improved quantification of cardiac amyloid burden in systemic light chain amyloidosis: redefining early disease?","volume":"13","author":"Cuddy","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.10.011_bib52","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/ehjci\/jead350","article-title":"Quantification of right ventricular amyloid burden with 18F-florbetapir positron emission tomography\/computed tomography and its association with right ventricular dysfunction and outcomes in light-chain amyloidosis","volume":"30","author":"Datar","year":"2024","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.10.011_bib53","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.2967\/jnumed.118.221770","article-title":"Early detection of multiorgan light-chain amyloidosis by whole-body 18F-florbetapir PET\/CT","volume":"60","author":"Ehman","year":"2019","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.jcmg.2024.10.011_bib54","first-page":"1419","article-title":"Cardiac amyloid quantification using 124I-evuzamitide (124I-P5+14) versus 18F-florbetapir: a pilot PET\/CT study","volume":"16","author":"Clerc","year":"2023","journal-title":"Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.10.011_bib55","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.jcmg.2023.08.009","article-title":"Cardiac amyloid detection by PET\/CT imaging of iodine (124I) evuzamitide (124I-p5+14): a phase 1\/2 study","volume":"16","author":"Wall","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.10.011_bib56","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s12350-021-02524-x","article-title":"Positron emission tomography for cardiac amyloidosis: timing matters","volume":"29","author":"Singh","year":"2022","journal-title":"J\u00a0Nucl Cardiol"},{"key":"10.1016\/j.jcmg.2024.10.011_bib57","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jcmg.2024.10.011_bib58","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","article-title":"Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis","volume":"133","author":"Lilleness","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jcmg.2024.10.011_bib59","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.jcmg.2024.10.011_bib60","first-page":"2008","article-title":"Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis","volume":"26","author":"Nitsche","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jcmg.2024.10.011_bib61","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","article-title":"Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis","volume":"2","author":"Cheng","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jcmg.2024.10.011_bib62","article-title":"Multiorgan dysfunction and associated prognosis in transthyretin cardiac amyloidosis","volume":"13","author":"Ioannou","year":"2024","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jcmg.2024.10.011_bib63","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ejhf.3094","article-title":"Albuminuria in transthyretin cardiac amyloidosis: prevalence, progression and prognostic importance","volume":"26","author":"Ioannou","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jcmg.2024.10.011_bib64","first-page":"333","article-title":"Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis","volume":"31","author":"Cohen","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2024.10.011_bib65","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.117.006588","article-title":"Independent prognostic value of stroke volume index in patients with immunoglobulin light chain amyloidosis","volume":"11","author":"Milani","year":"2018","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.10.011_bib66","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.cardfail.2018.07.001","article-title":"Myocardial contraction fraction by M-mode echocardiography is superior to ejection fraction in predicting mortality in transthyretin amyloidosis","volume":"24","author":"Rubin","year":"2018","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jcmg.2024.10.011_bib67","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/eurheartj\/ehu444","article-title":"T1 mapping and survival in systemic light-chain amyloidosis","volume":"36","author":"Banypersad","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2024.10.011_bib68","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","article-title":"Native T1 and extracellular volume in transthyretin amyloidosis","volume":"12","author":"Martinez-Naharro","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.10.011_bib69","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/ehjci\/jew325","article-title":"Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid","volume":"18","author":"Hutt","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.10.011_bib70","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis","volume":"1","author":"Castano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jcmg.2024.10.011_bib71","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jacc.2019.11.037","article-title":"Pittsburgh B compound positron emission tomography in patients with AL cardiac amyloidosis","volume":"75","author":"Lee","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2024.10.011_bib72","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2024.10.011_bib73","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2024.10.011_bib74","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmg.2024.10.011_bib75","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40259-023-00577-7","article-title":"RNA targeting and gene editing strategies for transthyretin amyloidosis","volume":"37","author":"Ioannou","year":"2023","journal-title":"BioDrugs"},{"key":"10.1016\/j.jcmg.2024.10.011_bib76","doi-asserted-by":"crossref","first-page":"30","DOI":"10.17925\/HI.2024.18.1.5","article-title":"Evolution of disease-modifying therapy for transthyretin cardiac amyloidosis","volume":"18","author":"Ioannou","year":"2024","journal-title":"Heart Int"},{"key":"10.1016\/j.jcmg.2024.10.011_bib77","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jacc.2023.12.036","article-title":"Stratifying disease progression in patients with cardiac ATTR amyloidosis","volume":"83","author":"Ioannou","year":"2024","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2024.10.011_bib78","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jacc.2024.04.011","article-title":"Prognostic value of a 6-minute walk test in patients with transthyretin cardiac amyloidosis","volume":"84","author":"Ioannou","year":"2024","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2024.10.011_bib79","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s11886-022-01703-7","article-title":"Imaging-guided treatment for cardiac amyloidosis","volume":"24","author":"Ioannou","year":"2022","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jcmg.2024.10.011_bib80","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004769","article-title":"TTR stabilizers are associated with improved survival in patients with transthyretin cardiac amyloidosis","volume":"11","author":"Rosenblum","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jcmg.2024.10.011_bib81","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/13506129.2021.2000388","article-title":"Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience","volume":"29","author":"Siddiqi","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.jcmg.2024.10.011_bib82","first-page":"1","article-title":"Left ventricular deformation and torsion assessed by speckle-tracking echocardiography in patients with mutated transthyretin-associated cardiac amyloidosis and the effect of diflunisal on myocardial function","volume":"9","author":"Koyama","year":"2015","journal-title":"Int J Cardiol Heart Vasc"},{"key":"10.1016\/j.jcmg.2024.10.011_bib83","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cardfail.2019.11.024","article-title":"Stabilization of cardiac function with diflunisal in transthyretin (ATTR) cardiac amyloidosis","volume":"26","author":"Lohrmann","year":"2020","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jcmg.2024.10.011_bib84","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jamacardio.2023.4147","article-title":"Effect of tafamidis on cardiac function in patients with transthyretin amyloid cardiomyopathy: a post hoc analysis of the ATTR-ACT randomized clinical trial","volume":"9","author":"Shah","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jcmg.2024.10.011_bib85","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/ehjci\/jead030","article-title":"Monitoring tafamidis treatment with quantitative SPECT\/CT in transthyretin amyloid cardiomyopathy","volume":"24","author":"Rettl","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.10.011_bib86","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.jcmg.2024.10.011_bib87","doi-asserted-by":"crossref","first-page":"e012135","DOI":"10.1161\/CIRCHEARTFAILURE.124.012135","article-title":"Effect of acoramidis on myocardial structure and function in transthyretin amyloid cardiomyopathy \u2014 insights from the ATTRibute-CM Cardiac Magnetic Resonance (CMR) substudy","volume":"17","author":"Razvi","year":"2024","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jcmg.2024.10.011_bib88","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2024.10.011_bib89","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmg.2024.10.011_bib90","first-page":"1","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.jcmg.2024.10.011_bib91","doi-asserted-by":"crossref","first-page":"27","DOI":"10.17925\/HI.2023.17.1.27","article-title":"Patisiran for the treatment of transthyretin-mediated amyloidosis with cardiomyopathy","volume":"17","author":"Ioannou","year":"2023","journal-title":"Heart Int"},{"key":"10.1016\/j.jcmg.2024.10.011_bib92","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmg.2024.10.011_bib93","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jcmg.2024.10.011_bib94","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cardfail.2023.11.016","article-title":"Effect of eplontersen on cardiac structure and function in patients with hereditary transthyretin amyloidosis","volume":"30","author":"Masri","year":"2024","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jcmg.2024.10.011_bib95","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in\u00a0vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmg.2024.10.011_bib96","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1056\/NEJMc2304584","article-title":"Antibody-associated reversal of ATTR amyloidosis\u2013related cardiomyopathy","volume":"388","author":"Fontana","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmg.2024.10.011_bib97","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmg.2024.10.011_bib99","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cardfail.2023.10.227","article-title":"The Peptide Fusion Immunoglobulin, AT-02, Exhibits Highly Potent Pan-Amyloid Reactivity And Immunomodulation","volume":"30","author":"Wall","year":"2024","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jcmg.2024.10.011_bib100","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jcmg.2024.10.011_bib101","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood.2020009039","article-title":"Phase 1a\/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis","volume":"138","author":"Edwards","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcmg.2024.10.011_bib102","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood.2022019406","article-title":"Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial","volume":"142","author":"Gertz","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jcmg.2024.10.011_bib103","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/ehjci\/jew298","article-title":"Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis","volume":"18","author":"Salinaro","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2024.10.011_bib104","first-page":"1","article-title":"Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment","volume":"00","author":"Martinez-Naharro","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2024.10.011_bib105","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1001\/jamacardio.2023.2010","article-title":"Tracking treatment response in cardiac light-chain amyloidosis with native T1 mapping","volume":"8","author":"Ioannou","year":"2023","journal-title":"JAMA Cardiol"}],"container-title":["JACC: Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936878X24004583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936878X24004583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T23:10:58Z","timestamp":1753312258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936878X24004583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":104,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1936878X24004583"],"URL":"https:\/\/doi.org\/10.1016\/j.jcmg.2024.10.011","relation":{},"ISSN":["1936-878X"],"issn-type":[{"value":"1936-878X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Last Decade in Cardiac Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"JACC: Cardiovascular Imaging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcmg.2024.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}